-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Factor XIa inhibitors used to prevent and treat venous and arterial thromboembolism may be more effective than conventional anticoagulants and reduce bleeding
Prevent thrombosis
Recently, a research article was published in the top medical journal NEJM.
The main efficacy outcome of the study is venous thromboembolism (it is the composite outcome of asymptomatic deep vein thrombosis, confirmed symptomatic venous thromboembolism, or death from any cause)
Among patients who took Milvexian twice a day, 27 of 129 patients (21%) who took 25 mg, 14 of 124 patients (11%) who took 50 mg, and 12 of 134 patients who took 100 mg Venous thromboembolism occurred in 10 (8%) of 131 patients who took 200 mg (9%) and 200 mg
It can be seen that in patients undergoing knee replacement surgery, oral milvexian inhibition of factor XIa after surgery can effectively prevent venous thromboembolism and is associated with a low risk of bleeding
In patients undergoing knee arthroplasty, oral milvexian inhibition of factor XIa after surgery can effectively prevent venous thromboembolism and is associated with a low risk of bleeding
